Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEK | Q02763 | 5/20 | 0.59 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.58 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.58 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.58 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.58 |
| ▸ | PRKD2 | Q9BZL6 | 3/20 | 0.58 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.58 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.58 |
| ▸ | FRK | P42685 | 2/20 | 0.58 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.58 |
| ▸ | MINK1 | Q8N4C8 | 2/20 | 0.58 |
| ▸ | CSNK1G1 | Q9HCP0 | 2/20 | 0.58 |
| ▸ | MAP3K20 | Q9NYL2 | 2/20 | 0.58 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.58 |
| ▸ | GSK3B | P49841 | 1/20 | 0.58 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.58 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.58 |
| ▸ | CSNK1G3 | Q9Y6M4 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4771368 | 0.86 | NR1I3 (0.52) | TEKFGFR1MAPK8MAPK9CSNK1D | |
| SCHEMBL4769730 | 0.86 | NR1I3 (0.55) | TEKNR1I3RPS6KA3CHEK2GAA | |
| SCHEMBL22633809 | 0.86 | NPC1 (0.57) | TEKALDH1A1PTGS2PTGS1NR1I3 | |
| SCHEMBL4767114 | 0.85 | TEK (0.60) | TEKPTGS2PTGS1NR1I3KDR | |
| SCHEMBL22633832 | 0.85 | NR1I3 (0.54) | TEKFGFR1MAPK8MAPK9CSNK1D | |
| SCHEMBL22633836 | 0.82 | NR1I3 (0.54) | TEKALDH1A1PTGS2NR1I3RPS6KA3 | |
| SCHEMBL22633918 | 0.82 | NR1I3 (0.54) | TEKFGFR1MAPK8MAPK9CSNK1D | |
| SCHEMBL13387977 | 0.82 | NPC1 (0.60) | TEKALDH1A1PTGS2NR1I3RPS6KA3 | |
| SCHEMBL25823477 | 0.82 | RPS6KA3 (0.48) | TEKNR1I3RPS6KA3CHEK2KDR | |
| SCHEMBL22633824 | 0.80 | NR1I3 (0.55) | TEKALDH1A1PTGS2NR1I3RPS6KA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11701345-B2 | Car activator agents for cyclophosphamide-based treatments of cancer | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-07-18 | — | — | US | disclosed |
| US-11701345-B2 | Car activator agents for cyclophosphamide-based treatments of cancer | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-07-18 | — | — | US | disclosed |
| US-11701345-B2 | Car activator agents for cyclophosphamide-based treatments of cancer | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-07-18 | — | — | US | disclosed |
| US-20200352915-A1 | CAR ACTIVATOR AGENTS FOR CYCLOPHOSPHAMIDE-BASED TREATMENTS OF CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-11-12 | — | — | US | disclosed |
| US-20200352915-A1 | CAR ACTIVATOR AGENTS FOR CYCLOPHOSPHAMIDE-BASED TREATMENTS OF CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-11-12 | — | — | US | disclosed |
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-10676484-B2 | Compositions and methods for treating leukemia | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-20200148702-A1 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS | DANA FARBER CANCER INST INC (US) | 2020-05-14 | — | — | US | disclosed |
| US-10407441-B2 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-20180222917-A1 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | COLD SPRING HARBOR LABORATORY | 2018-08-09 | — | — | US | disclosed |
| US-20130252331-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLISM | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-09-26 | — | — | US | disclosed |
| US-20130252331-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLISM | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-09-26 | — | — | US | disclosed |
| US-20130210813-A1 | Male Contraceptive Compositions and Methods of Use | DANA-FARBER CANCER INSTITUTE, INC. | 2013-08-15 | — | — | US | disclosed |
| US-20130210813-A1 | Male Contraceptive Compositions and Methods of Use | DANA-FARBER CANCER INSTITUTE, INC. | 2013-08-15 | — | — | US | disclosed |
| US-20130184264-A1 | Compositions And Methods For Treating Neoplasia, Inflammatory Disease And Other Disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-07-18 | — | — | US | disclosed |
| US-20120271054-A1 | IMIDAZOTHIAZOLE-CHALCONE DERIVATIVES AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2012-10-25 | — | — | US | disclosed |
| EP-1575963-B1 | ANTI-ANGIOGENETIC THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2008-05-07 | — | — | EP | disclosed |
| US-20060069109-A1 | Therapeutic agents | ASTRAZENECA AB (SE) | 2006-03-30 | — | — | US | disclosed |
| EP-1575963-A1 | THERAPEUTIC AGENTS | AstraZeneca AB (SE) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004058776-A1 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | BRDT, BRD4, BRD1 | TEK 2856/4885FGFR1 2887/4885MAPK8 2048/4885 |
| US-10407441-B2 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | BRPF3, EP300, BRD3 | TEK 3377/4885FGFR1 3333/4885MAPK8 3181/4885 |
| US-11701345-B2 | Car activator agents for cyclophosphamide-based treatments of cancer | CYP2A6, CYP2B6, CYP4A11 | TEK 3351/4885FGFR1 2814/4885MAPK8 3080/4885 |
| US-10676484-B2 | Compositions and methods for treating leukemia | MCL1, ABL1, FLT3 | TEK 916/4885FGFR1 2133/4885MAPK8 3296/4885 |
| US-20130210813-A1 | Male Contraceptive Compositions and Methods of Use | SHBG, CYP19A1, CYP17A1 | TEK 2195/4885FGFR1 4563/4885MAPK8 4766/4885 |
| US-20060069109-A1 | Therapeutic agents | TIE1, TEK, KDR | TEK 2/4885FGFR1 37/4885MAPK8 666/4885 |
| US-20180222917-A1 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | MCL1, ABL1, FLT3 | TEK 916/4885FGFR1 2133/4885MAPK8 3296/4885 |
| US-20200352915-A1 | CAR ACTIVATOR AGENTS FOR CYCLOPHOSPHAMIDE-BASED TREATMENTS OF CANCER | CYP2A6, CYP2B6, CYP4A11 | TEK 3351/4885FGFR1 2814/4885MAPK8 3080/4885 |
| US-20130184264-A1 | Compositions And Methods For Treating Neoplasia, Inflammatory Disease And Other Disorders | BRPF3, EP300, BRD3 | TEK 3377/4885FGFR1 3333/4885MAPK8 3181/4885 |
| US-20130252331-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLISM | BRD3, BRD2, BRD4 | TEK 3496/4885FGFR1 2205/4885MAPK8 2512/4885 |
| US-20200148702-A1 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS | BRPF3, EP300, BRD3 | TEK 3377/4885FGFR1 3333/4885MAPK8 3181/4885 |
| US-20120271054-A1 | IMIDAZOTHIAZOLE-CHALCONE DERIVATIVES AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | EIF4A1, CYP2C18, UGT2B17 | TEK 2466/4885FGFR1 246/4885MAPK8 805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.